Adicet Bio (ACET) Canaccord Genuity’s 45th Annual Growth Conference summary

Overview of allogeneic Gamma-delta CAR-T cell approach

• Off-the-shelf Gamma-delta 1-T cell therapies offer differentiated safety and robust tissue exposure, enabling outpatient dosing and targeting organ damage in autoimmune diseases.

• Programs are enrolling patients with SLE, lupus nephritis, and systemic sclerosis; a solid tumor program will enter the clinic next year.

• Gamma-delta 1-T cells provide superior tissue penetration and consistent B cell killing compared to autologous alpha-beta T cell therapies.

Advantages over autologous therapies

• Off-the-shelf products eliminate the need for leukapheresis and personalized manufacturing, reducing wait times and variability.

• Lower IL-6 secretion leads to reduced CRS and neurotoxicity, allowing outpatient administration by rheumatologists.

• No prolonged immunosuppression withdrawal is required, improving patient safety and convenience.

Target selection and mechanism

• CD20 was chosen as the target due to its stability and overlap with CD19, enabling effective B cell depletion in blood and tissues.

• Functional outcomes mirror autologous CD19 therapies, with complete B cell depletion observed.